NasdaqGS:ZYMEBiotechs
Zymeworks (ZYME) Stock Rich Valuation Meets Widening Losses
Zymeworks stock inched up 1.8% to US$23.54 into the close, a calm move for a biotech that just posted another hefty quarterly loss. The headline is simple. Revenue stayed modest at US$4.59 million while net loss widened to about US$45 million. The short term story is about cash burn and a thin top line.
The longer term story is very different. Forecasts in available analyst reports point to a path to profitability, yet the stock already trades on a rich P/S multiple. That tension between...